TELA Bio, Inc. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$21M↑+18.2%
2025-09-30$21M↑+9.1%$-9M↑+17.1%-36.5%
2025-06-30$20M↑+25.5%$-10M↑+21.2%-45.0%
2025-03-31$19M↑+11.5%$-11M↓-99.0%-56.5%
2024-12-31$18M↑+3.8%
2024-09-30$19M↑+25.9%$-10M↑+5.3%-49.4%
2024-06-30$16M↑+11.0%$-13M↓-16.8%-71.9%
2024-03-31$17M↑+39.4%$-6M↑+52.9%-29.1%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$21M
↑+18.2% +$3M YoY
Net Income
$9M
↑+26.4% +$2M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 31 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+2.3pts
65.9%
Operating Margin↑+12.9pts
-36.5%
Net Margin↑+13.1pts
-41.6%

Go deeper